Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma

Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients
                           With Metastatic Melanoma

PR Newswire

THOUSAND OAKS, Calif., April 4, 2014

THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ --Amgen (NASDAQ: AMGN)
today announced top-line results from the primary overall survival (OS)
analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and
safety of talimogene laherparepvec for the treatment of unresected stage IIIB,
IIIC or IV melanoma compared to treatment with subcutaneous
granulocyte-macrophage colony-stimulating factor (GM-CSF). Results showed
that, while the primary end point of durable response rate was met (as
previously reported), the secondary endpoint of OS was not met, although there
was a strong trend in favor of talimogene laherparepvec (p=0.051). The
estimated OS hazard ratio and improvement in median OS were similar to what
was previously reported at the interim OS analysis.

Talimogene laherparepvec is an investigational oncolytic immunotherapy
designed to selectively replicate in tumors and to initiate an immune response
to target cancer that has metastasized, or spread to other areas of the body.

"We remain encouraged that the study met its primary endpoint of achieving
durable responses in patients with metastatic melanoma," said Sean E. Harper,
M.D., executive vice president of Research and Development at Amgen. "We
missed statistical significance on the secondary endpoint of overall survival
but the strong trend in survival benefit supports further research of
talimogene laherparepvec to better understand its role in melanoma, both as a
single-agent and in combination with other therapies."

The global, randomized, open-label Phase 3 trial enrolled patients with
unresected stage IIIB, IIIC or IV melanoma. Patients were randomized 2:1 to
receive either talimogene laherparepvec every two weeks through direct tumor
injection or GM-CSF subcutaneously for the first 14 days of each 28-day cycle,
for up to 18 months.

The most frequent adverse events observed in this trial were fatigue, chills
and pyrexia. The most common serious adverse events include disease
progression, cellulitis and pyrexia.

About Talimogene Laherparepvec
Talimogene laherparepvec is an investigational oncolytic immunotherapy
designed to selectively replicate in tumors (but not normal tissue) and to
initiate an immune response to target cancer cells that have metastasized.
Talimogene laherparepvec was designed to work in two important and
complementary ways. First, it is injected directly into tumors where it
replicates inside the tumor's cells causing the cell to rupture and die in a
process called lysis.The rupture of the cancer cells can release
tumor-derived antigens, along with GM-CSF, that can stimulate a system-wide
immune response where white blood cells are able to seek out and target cancer
that has spread throughout the body.

About Melanoma
Melanoma is a type of skin cancer that is characterized by the uncontrolled
growth of melanocytes, which are the cells responsible for providing the
pigment to skin.^1 Melanoma is the most aggressive and serious form of skin
cancer. Currently, 132,000 melanoma cases occur globally each year.^2 In the
U.S., while melanoma accounts for less thanfive percent of skin cancer cases,
it causes the most skin cancer deaths.^2 The number of new cases of melanoma
in the U.S. has been increasing for the last 30 years.^2

Melanoma is considered to be advanced when it has spread, or metastasized,
from the origin site to deeper parts of the skin or other organs such as the
lymph nodes, lungs or other parts of the body distant from the primary tumor
site.^3

AboutAmgen
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on the
current expectations and beliefs of Amgen Inc. and its subsidiaries (Amgen or
us) and are subject to a number of risks, uncertainties and assumptions that
could cause actual results to differ materially from those described. All
statements, other than statements of historical fact, are statements that
could be deemed forward-looking statements, including estimates of revenues,
operating margins, capital expenditures, cash, other financial metrics,
expected legal, arbitration, political, regulatory or clinical results or
practices, customer and prescriber patterns or practices, reimbursement
activities and outcomes and other such estimates and results. Forward-looking
statements involve significant risks and uncertainties, including those
discussed below and more fully described in the Securities and Exchange
Commission (SEC) reports filed by Amgen Inc., including Amgen Inc.'s most
recent annual report on Form 10-K and any subsequent periodic reports on Form
10-Q and Form 8-K. Please refer to Amgen Inc.'s most recent Forms 10-K, 10-Q
and 8-K for additional information on the uncertainties and risk factors
related to our business. Unless otherwise noted, Amgen is providing this
information as of April 4, 2014, and expressly disclaims any duty to update
information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project. Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans. The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it
takes for us and our partners to complete clinical trials and obtain
regulatory approval for product marketing has in the past varied and we expect
similar variability in the future. We develop product candidates internally
and through licensing collaborations, partnerships and joint ventures. Product
candidates that are derived from relationships may be subject to disputes
between the parties or may prove to be not as effective or as safe as we may
have believed at the time of entering into such relationship. Also, we or
others could identify safety, side effects or manufacturing problems with our
products after they are on the market. Our business may be impacted by
government investigations, litigation and product liability claims. If we fail
to meet the compliance obligations in the corporate integrity agreement
between us and the U.S. government, we could become subject to significant
sanctions. We depend on third parties for a significant portion of our
manufacturing capacity for the supply of certain of our current and future
products and limits on supply may constrain sales of certain of our current
products and product candidate development.

In addition, sales of our products (including products of our wholly-owned
subsidiaries) are affected by the reimbursement policies imposed by
third-party payers, including governments, private insurance plans and managed
care providers and may be affected by regulatory, clinical and guideline
developments and domestic and international trends toward managed care and
healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. In addition, we compete with other companies with respect to
some of our marketed products as well as for the discovery and development of
new products. We believe that some of our newer products, product candidates
or new indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against products that
have lower prices, established reimbursement, superior performance, are easier
to administer, or that are otherwise competitive with our products. In
addition, while Amgen and its partners routinely obtain patents for their
products and technology, the protection of our products offered by patents and
patent applications may be challenged, invalidated or circumvented by our or
our partners' competitors and there can be no guarantee of our or our
partners' ability to obtain or maintain patent protection for our products or
product candidates. We cannot guarantee that we will be able to produce
commercially successful products or maintain the commercial success of our
existing products. Our stock price may be affected by actual or perceived
market opportunity, competitive position, and success or failure of our
products or product candidates. Further, the discovery of significant problems
with a product similar to one of our products that implicate an entire class
of products could have a material adverse effect on sales of the affected
products and on our business and results of operations. Our efforts to
integrate the operations of companies we have acquired may not be successful.

The scientific information discussed in this news release related to our
product candidates is preliminary and investigative. Such product candidates
are not approved by the U.S. Food and Drug Administration (FDA), and no
conclusions can or should be drawn regarding the safety or effectiveness of
the product candidates.

CONTACT: Amgen
Wendy Woods Williams, 805-447-6382  (media)
Arvind Sood, 805-447-1060 (investors)

References:

^1 National Cancer Institute,National Institute of Health,U.S. Dept. of
Health and Human Services.What You Need to Know About Melanoma and Other Skin
Cancers. June 2010 http://www.cancer.gov/cancertopics/wyntk/skin. Accessed
February 21, 2014.

^2 Ultraviolet radiation and the INTERSUN Programme.World Health
Organization. http://www.who.int/uv/intersunprogramme/en/. AccessedFebruary
21, 2014.^

^3American Cancer Society. Melanoma Skin
Cancer.http://www.cancer.org/acs/groups/cid/documents/webcontent/003120-pdf.pdf.
AccessedFebruary 21, 2014.

Amgen Logo.

Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO

SOURCE Amgen

Website: http://www.amgen.com
 
Press spacebar to pause and continue. Press esc to stop.